| Literature DB >> 22646689 |
Caroline Deshayes1, Magdalena K Bielecka, Robert J Cain, Mariela Scortti, Aitor de las Heras, Zbigniew Pietras, Ben F Luisi, Ricardo Núñez Miguel, José A Vázquez-Boland.
Abstract
The transcriptional regulator PrfA controls key virulence determinants of the facultative intracellular pathogen Listeria monocytogenes. PrfA-dependent gene expression is strongly induced within host cells. While the basis of this activation is unknown, the structural homology of PrfA with the cAMP receptor protein (Crp) and the finding of constitutively activated PrfA* mutants suggests it may involve ligand-induced allostery. Here, we report the identification of a solvent-accessible cavity within the PrfA N-terminal domain that may accommodate an activating ligand. The pocket occupies a similar position to the cAMP binding site in Crp but lacks the cyclic nucleotide-anchoring motif and has its entrance on the opposite side of the β-barrel. Site-directed mutations in this pocket impaired intracellular PrfA-dependent gene activation without causing extensive structural/functional alterations to PrfA. Two substitutions, L48F and Y63W, almost completely abolished intracellular virulence gene induction and thus displayed the expected phenotype for allosteric activation-deficient PrfA mutations. Neither PrfA(allo) substitution affected vacuole escape and initial intracellular growth of L. monocytogenes in epithelial cells and macrophages but caused defective cell-to-cell spread and strong attenuation in mice. Our data support the hypothesis that PrfA is allosterically activated during intracellular infection and identify the probable binding site for the effector ligand. They also indicate that PrfA allosteric activation is not required for early intracellular survival but is essential for full Listeria virulence and colonization of host tissues.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22646689 PMCID: PMC3443378 DOI: 10.1111/j.1365-2958.2012.08121.x
Source DB: PubMed Journal: Mol Microbiol ISSN: 0950-382X Impact factor: 3.501
Fig. 1The ‘phosphate binding cassette’ (PBC) is absent from PrfA and other CNBD-containing proteins not regulated by cyclic nucleotide monophosphates (cNMP). A. Amino acid sequence alignment of the CNBD β6–β7 region in a selection of bacterial and eukaryotic proteins regulated and not regulated by cNMP. Conserved blocks of sequence are shown in red and residues known to interact with the cNMP molecule are shaded green. Numbering above the sequences corresponds to Crp, the position of β-strands 6 and 7 of the β-barrel is indicated by arrows. clustalw2 alignment (http://www.ebi.ac.uk/Tools/clustalw2/) visualized with ESPript (http://espript.ibcp.fr/; Gouet ). cNMP-regulated proteins: E. coli Crp/Cap (P0ACK0); Homo sapiens PrkG1 (Q13976), Prkar2A (P13861, CNG1 (P29973) and Epac1 (O95398); Bos taurus Pka (P00514); Oryctolagus cuniculus HCN1 (Q9MZS1); Mus musculus Epac2 (Q9EQZ6); Rhodopseudomonas palustris RpalK1 (Q02006); Rhizobium loti MlotiK1 (Q98GN8); Pseudomonas aeruginosa Vfr (P55222); Mycobacterium tuberculosis MT3777 (O69644). cNMP-non-regulated proteins and corresponding effector ligands: E. coli Fnr (P0A9E5), oxygen (Green ); Rhodospirillum rubrum CooA (P72322), haem-CO (Lanzilotta ); P. aeruginosa Dnr (Q51441), haem-NO (Giardina ); Desulfitobacterium hafniense CprK (B8FW11), ortho-chlorophenolacetic acid (Levy ); Anabaena variabilis NtcA (P0A4U7), 2-oxoglutarate (Vazquez-Bermudez ); L. monocytogenes PrfA (P22262), unknown. EMBL accession numbers in parentheses. B. Unrooted neighbour-joining phylogenetic tree of sequences included in the alignment shown in (A). The branch containing only cNMP-non-regulated CNBD proteins is shown in red. Constructed with Phylip 3.69 (http://evolution.genetics.washington.edu/phylip.html) and visualized using FigTree (http://tree.bio.ed.ac.uk/software/figtree/).
Fig. 2Position and trajectories of the PrfA N-terminal domain pocket and Crp cAMP-binding pocket. Ribbon representation (with surface in transparency) of ‘side’ and ‘top’ views of the crystal structures of PrfA (PDB code 2BEO) and the cAMP–Crp complex (PDB code 1G6N). The solvent-accessible access channel as determined by caver (Petrek ) is shown in green. A smaller ‘side’ view of the PrfA and Crp dimers in surface-only representation is shown for reference. The ‘top’ view is a 90° rotation with the arrowhead brought to the foreground. In both structures, one protomer is coloured light grey with the N-terminal domain in pink, the other protomer is dark grey. The PBC loop (and corresponding region in PrfA) is in red. The additional C-terminal GHI helical bundle of PrfA is in yellow. In Crp, the cAMP molecule is in sphere representation with atoms coloured by element (C, yellow; O, red; N, blue).
Fig. 3Site-directed mutagenesis of surface-exposed residues of the PrfA N-terminal domain pocket. Mutated residues are represented as orange sticks in a detail of the cutaway cross-section of the PrfA dimer shown in Fig. S4A, in which the two halves of the internal surface of one of the pockets is shown. The green volume in mesh representation is the pocket trajectory determined by caver (Petrek ). Note that the caver graphical output represents the solvent access path and does not fill the entire volume of the distal chamber's (dc) cavity. See also Fig. S5 for additional reference.
Fig. 4Effect of PrfA pocket substitutions on intracellular virulence gene activation. Expression from the PrfA-regulated promoters PplcA and PactA was analysed by RT-QPCR in extracellular and intracellular conditions [respectively: exponentially growing BHI culture (OD600 = 0.3) and HeLa cells infected for 6 h]. L. monocytogenesΔprfA was complemented with the following prfA constructs: ΔprfA, vector with no insert; prfAWT, wild-type allele; substitutions in single-letter code, prfA pocket mutant alleles; see Table S2. P14 is the isogenic wild-type parent strain of the ΔprfA strain used to express the prfA constructs. Numbers above bars, per cent intracellular activation relative to prfAWT. Statistically significant differences (P ≤ 0.01) indicated by asterisks. Mean of at least three independent experiments ± SEM.
Biophysical characterization of PrfA pocket mutant proteins
| Specific DNA-binding affinity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Dimerization | Thermal stability | P | P | |||||
| PrfA substitution | Description | MW (kDa) | % peak integration | % PrfAWT | % PrfAWT | |||
| None (PrfAWT) | Activable | 58.3 ± 9.8 | 95.5 | 61.8 ± 1.3 | 1096 ± 49 | 100 | 1363 ± 24 | 100 |
| G145S (PrfA*) | Constitutively activated | 54.4 ± 5.6 | 83.9 | 54.5 ± 1.0 | ≤ 1 | – | ≤ 1 | – |
| G145S/E173G (PrfA*sup) | DNA binding-deficient | 53.3 ± 3.4 | 81.3 | 52.0 ± 0.5 | 10518 ± 317 | 9 | 32022 ± 528 | 4 |
| F29M | Group III (−) | 49.0 ± 14.9 | 96.0 | 59.8 ± 0.3 | 288 ± 45 | 381 | 267 ± 15 | 510 |
| E36Q | Group II (+) | 59.4 ± 12.4 | 85.3 | 65.5 ± 0.5 | 1356 ± 11 | 81 | 801 ± 67 | 170 |
| E36R | Group II (++) | 52.0 ± 3.0 | 86.8 | 66.5 ± 0.5 | 1445 ± 13 | 76 | 1079 ± 10 | 126 |
| L48F | Group I (++++) | 50.4 ± 4.7 | 90.9 | 51.3 ± 0.3 | 5265 ± 101 | 21 | 20842 ± 262 | 7 |
| Y63W | Group II (++++) | 50.0 ± 3.0 | 84.4 | 59.3 ± 2.0 | 1158 ± 86 | 95 | 1660 ± 14 | 82 |
| I69W | Group II (++) | 49.0 ± 7.8 | 92.9 | 57.5 ± 0.0 | 347 ± 43 | 316 | 392 ± 76 | 348 |
| S71L | Group II (+++) | 50.3 ± 3.0 | 83.3 | 54.3 ± 0.3 | 695 ± 42 | 158 | 741 ± 59 | 184 |
| V80L | Group III (−) | 52.0 ± 4.9 | 92.6 | 62.0 ± 0.0 | 1785 ± 47 | 61 | 1404 ± 54 | 97 |
| L120V | Group II (+++) | 50.7 ± 3.1 | 92.3 | 60.2 ± 0.2 | 3123 ± 37 | 35 | 1586 ± 17 | 86 |
| L48F/G145S | Double mutant | 49.8 ± 7.0 | 93.3 | nd | 15 ± 1 | 7362 | 239 ± 60 | 571 |
| Y63W/G145S | Double mutant | 51.3 ± 3.1 | 83.0 | nd | 9 ± 1 | 11617 | 29 ± 1 | 4754 |
| S71L/G145S | Double mutant | 51.3 ± 6.3 | 72.9 | nd | 75 ± 1 | 1465 | 67 ± 1 | 2039 |
Intracellular activation phenotype grouping for PrfA pocket single substitutions (see Fig. 4): group I = activation-deficient; group II = activation-impaired; group III = wild-type activation. Rating of activation defect relative to PrfAWT: (−) = no activation defect; (+) to (++++) = weak to very strong effect.
N-terminal domain pocket/C-terminal domain PrfA* G145S double mutant.
A dimerization-deficient PrfA mutant was used as negative control (PrfA*G145S/A129T, experimentally determined MW = 32.3 kDa; M. K. Bielecka et al., in preparation).
Note that the Tm for PrfA*G145S was 7.2°C lower than that for PrfAWT, indicating that the structural changes associated with the G145S substitution make the hyperactive mutant protein slightly less stable.
This PrfA box is shared by the promoters of the divergently transcribed PrfA-regulated genes plcA (PlcA phospholipase) and hly (LLO pore-forming toxin).
Precise KD values could not be determined for the constitutively hyperactive PrfA*G145S mutant; likely due to the avidity for its target DNA sequence, the dissociation rate could not be reliably determined and quantified with the Biacore instrument. An analogous situation was previously reported by Mauder for PrfA*G145S.
MW, molecular weight determined by analytical ultracentrifugation. Tm, thermal denaturation midpoint temperature determined by fluorescence enhancement of the hydrophobic reporter dye Sypro Orange. KD, equilibrium dissociation constant in nM determined using the PrfA boxes of the PplcA/hly and PactA promoters as target sequence (relative DNA-binding affinity expressed as percentage of PrfAWT). nd, not determined. Data are average values ± SEM.
Fig. 5Effect of PrfA pocket substitutions on L. monocytogenes cell-to-cell spread. Plaque assay in murine L929 fibroblasts. Bacteria as in Fig. 4. Negative control: isogenic ΔactA mutant lacking the actin-polymerizing surface protein ActA essential for cell-to-cell spread (Kocks ). Numbers above bars, relative spreading of mutants as quantified by average plaque size, expressed in percentage of prfAWT; see Fig. S8 for representative images of the sizes of the plaques. Mean of at least three independent experiments ± SEM; asterisks, statistically significant differences (P ≤ 0.01). Note that despite the marked differences in extracellular (BHI) PrfA-dependent expression levels between prfAWT and prfA*G145S, both exhibited the same (maximal) levels of spread, supporting the notion that the PrfA*G145S mutant protein mimics the ON (intracellular) PrfA state.
Fig. 6Intracellular growth of prfAallo mutants in HeLa cells. L. monocytogenesΔprfA complemented with an empty vector or prfAWT allele were used as controls. Inset, intracellular growth dynamics at early time points of infection. Data were normalized using an intracellular growth coefficient (IGC) (see Experimental procedures) and expressed as per cent of wild type at t = 8. Bacterial cfu counts per well at t = 0: prfAWT, 4.3 ± 1.0 × 103; prfA*G145S, 13.1 ± 8.4 × 103; prfAL48F, 2.2 ± 0.3 × 103; prfAY63W, 4.4 ± 0.8 × 103; ΔprfA, 2.7 ± 0.8 × 103. Mean of at least two duplicate experiments ± SEM. Statistically significant differences (P ≤ 0.01) indicated by asterisks.
Fig. 7Vacuole escape of prfAallo mutants in HeLa cells. A. Vacuole escape dynamics for prfAWT and prfAallo L48F and Y63W strains determined by fluorescence microscopy. Infected HeLa cells were quantified for association with vacuolar (Rab7) or cytosolic (F-actin rings and tails) markers in an intracellular infection time-course. Mean of three independent experiments ± SEM. B. Representative fluorescence micrographs used to quantify vacuole escape in (A). White boxes in top panels (Rab7, F-actin and DAPI staining merge) indicate areas of interest and are shown as 2.5× magnified sections below: (a) image of boxed area; (b) Rab7 vacuole staining, clearly evident around bacteria at 30 min but not at 90 min; (c) F-actin staining, which is not associated with bacteria at 30 min but present as actin rings at 90 min for all strains, and as actin tails for prfAWT but not prfAallo (L48F and Y63W) strains; (d) DAPI staining, showing internalized bacteria. Data for each time point are the mean percentage of five microscopic fields per experiment, and three independent experiments. Images were originally captured at 630× magnification.
Fig. 8Mouse virulence tests. Competitive assay in which BALB/c mice (n = 9 per group) were inoculated i.v. with ≍ 103 cfu of a ≍ 1:1 mixture of prfAWT and prfAallo mutant. Bacterial loads monitored in spleen and liver at the indicated time points. Bars represent the total cfu per organ expressed in log units with indication of the proportion of prfAWT and prfAallo bacteria.